One gene variant is the strongest known genetic risk factor for Alzheimer’s. Here’s what it means — and what you can do about it.
There’s a gene that researchers now consider the single strongest genetic risk factor for late-onset Alzheimer’s disease.
It’s called APOE — apolipoprotein E. Most people have never heard of it. But for anyone paying attention to brain health, it may be the most actionable piece of genetic information available. Here’s what it is, what it means, and why the people who carry the highest-risk variant are often the ones who respond most to what we do in VitalLife.
What the APOE gene does
Every gene in your body works the same basic way: it carries instructions. Your APOE gene instructs your body on how to produce apolipoprotein E, a protein that does two critical jobs. First, it manages how your body transports cholesterol and fats through the bloodstream. Second — and this is the part that matters for your brain — it plays a central role in how your brain clears amyloid-beta, the protein fragment whose accumulation is the hallmark of Alzheimer’s disease.
When the APOE gene gives clear, effective instructions, your brain’s cleanup system runs well. When the instructions are compromised, amyloid builds up, inflammation increases, and the metabolic environment of the brain begins to shift in ways that increase Alzheimer’s risk.
The version of the gene you inherited determines how well those instructions work.
The three versions — and what each one means
APOE comes in three forms, called alleles: ε2, ε3, and ε4. Everyone inherits two copies — one from each parent. The combination you carry is your APOE genotype, and it’s one of the strongest genetic predictors of Alzheimer’s risk identified in modern research.
APOE ε2 — The protective variant
The rarest of the three, carried by roughly 5–10% of the population. Carrying even one copy of ε2 appears to reduce Alzheimer’s risk by up to 40% compared to the most common variant. When Alzheimer’s does occur in ε2 carriers, it tends to develop later in life.
APOE ε3 — The neutral variant
The most common form, present in approximately 78% of alleles worldwide. ε3 is used as the research baseline — neither increasing nor decreasing Alzheimer’s risk. Most people carry at least one copy.
APOE ε4 — The risk variant
Present in approximately 14–15% of the general population, but found in an estimated 40% of late-onset Alzheimer’s patients. This is the variant Dr. Pardue wants every patient to know about.
One copy of ε4 (ε3/ε4): 2–3x increased risk of Alzheimer’s
Two copies of ε4 (ε4/ε4): 8–12x increased risk — the highest genetic risk profile
To put that in perspective: approximately 2–5% of the population carries two copies of ε4. That group faces a significantly earlier average age of onset and the steepest risk curve of any common genetic variant associated with Alzheimer’s.
And carrying ε4 does not mean Alzheimer’s is inevitable. That distinction matters, and we’ll come back to it.
Why ε4 changes how the brain works
The ε4 variant doesn’t just increase risk on paper. It changes the brain’s operating environment in measurable ways — some of which begin decades before any symptoms appear.
APOE4 impairs the brain’s ability to clear amyloid-beta effectively, allowing it to accumulate earlier and faster than in ε3 carriers. It also disrupts glucose metabolism in the brain — meaning ε4 carriers’ neurons are less efficient at using their primary fuel source. Research has found that these glucose metabolism differences can appear in cognitively normal APOE4 carriers decades before any cognitive symptoms emerge.
APOE4 also promotes neuroinflammation and impairs lipid transport in the brain — two factors directly linked to the synaptic damage that underlies memory loss.
This is why Dr. Pardue calls it an operating environment problem, not just a risk statistic. The brain of an ε4 carrier functions differently. And that means the interventions that matter most are the ones that address that underlying metabolic environment.
The patients at highest risk respond best to metabolic intervention
Here is what Dr. Pardue has observed consistently in his patients — and what the emerging research supports:
“People who carry two copies of APOE4 are the ones I feel most urgency about. Their risk is real and it’s elevated. But they are also, in my clinical experience, the patients who respond most favorably to the kind of metabolic work we do in VitalLife.
When the brain has been running in a compromised state for years, and you give it what it actually needs — the right nutrition, sleep, exercise and peace – the response can be dramatic.
Genetics loads the gun. Lifestyle pulls the trigger. It works the other way too: the right lifestyle can keep that trigger from ever being pulled.”
— Dr. Randy Pardue
The underlying research points the same way. Studies have found that because APOE4 impairs glucose metabolism in the brain, ε4 carriers appear to shift metabolic dependency toward ketones — an alternative fuel source. Interventions that support metabolic flexibility, reduce insulin resistance, and optimize the brain’s fuel supply show particular promise for this population. The VitalLife protocols are built around exactly that substrate.
Should you get tested?
This is a question worth thinking through carefully — not because the answer is complicated, but because knowing your APOE status carries real weight, and you should go in prepared.
The case for knowing: If you carry ε4 — one copy or two — that information gives you a concrete reason to act now rather than later. The interventions that protect cognitive health work best when they start early, before any symptoms appear. Knowing your status gives you something real to work with — and a clear reason to start now rather than wait.
One important note before you test: Federal law (GINA) protects you from genetic discrimination by health insurers and most employers — but that protection does not extend to life insurance, long-term care insurance, or disability insurance. If you don’t currently have those policies and plan to get them, it may be worth doing so before you learn your APOE status, since a positive result could affect your eligibility or premiums.
How to get tested: You have two main paths.
Through a physician:
Ask your doctor to order an APOE genotyping test. Many cardiologists run it routinely, since ε4 also affects cardiovascular risk. Results come through your medical record, and a knowledgeable physician can help you interpret them. Dr. Pardue is happy to discuss your results as part of the VitalLife program.
Direct-to-consumer:
23andMe offers FDA-approved APOE testing. One note of caution: 23andMe reports on only one of the two genetic markers used to determine full APOE status, which means results can be incomplete — particularly for identifying ε4/ε4 carriers. If you use a DTC test, a service that reports both relevant SNPs (rs429358 and rs7412) gives you the full picture. Dr. Pardue can help you interpret your raw data if you already have results from 23andMe or AncestryDNA.
Either way: if the results show ε4 — especially two copies — bring them to someone who knows what to do with that information.
The VitalLife Brain Health Program was built around this.
Whether you’ve already tested positive for ε4, suspect you’re at risk based on family history, or simply want to get ahead of cognitive decline before any symptoms appear — this cohort was designed with you in mind.
Dr. Pardue will walk you through how to read your own metabolic and genetic risk markers, and what to actually do about them. Nutrition, sleep, movement, and peace — through the specific lens of protecting your brain.
Knowing your genetic risk is the starting point. What you do with that information is the story.
Two options to join us:
📅 Free Preview Night
Come see what the program is about, meet Dr. Pardue, ask your questions, and decide if it’s right for you. No obligation.
→ Reserve your spot at the Preview Night: REGISTER
🚀 VitalLife Brain Health Cohort Begins
→ Learn more about the VitalLife program: LEARN MORE
For your health,
— Adam (on behalf of Dr. Pardue)
865.306.015
P.S. If you already know your APOE status and carry the ε4 variant — one copy or two — come to the Preview Night. Dr. Pardue wants to talk with you personally before the cohort begins.